Amelioration and treatment of chronic lung disease using pluripotent stem cells
The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in the regenerative medicine area. Provided are a cell preparation and a medicinal composition for ameliorating and treating chronic lung disease in newborns, said cell preparation and medicinal composition comprising SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue in a living body or cultured mesenchymal cells. The cell preparation according to the present invention is based on a mechanism whereby the aforesaid disease is ameliorated and treated by administering Muse cells to a subject suffering from the disease and engrafting the cells in lung tissues.
1. A method of treating persistent pulmonary hypertension of the human newborn (PPHN) and/or hypertension of the human newborn caused by chronic lung disease, the method comprising:
(i) intravenously administering a therapeutically effective amount of human pluripotent stem cells to a human newborn that has PPHN and/or hypertension of the human newborn caused by chronic lung disease,
wherein the human pluripotent stem cells are isolated from mesenchymal tissue, and
wherein the human pluripotent stem cells express SSEA-3 and CD105 but do not express CD117 and CD146, have low or no telomerase activity; have the capability to differentiate into any of three germ layers; exhibit no neoplastic proliferation; and have ability to self-renewal.
2. The method according to claim 1 , wherein the human pluripotent stem cells positive for SSEA-3 have been concentrated by external stress treatment.
3. The method according to claim 1 , wherein the human pluripotent stem cells are CD117-negative, CD146-negative, NG2-negative, CD34-negative, vWF-negative, and CD271-negative.
4. The method according to claim 1 , wherein the human pluripotent stem cells are CD34-negative, CD117-negative, CD146-negative, CD271-negative, NG2-negative, vWF-negative, Sox10-negative, Snail-negative, Slug-negative, Tyrp1-negative, and Dct negative.
5. The method according to claim 1 , wherein the therapeutically effective amount of human pluripotent stem cells is from approximately 1×10 4 cells/individual to approximately 3×10 8 cells/individual.
6. The method according to claim 1 , wherein the therapeutically effective amount of human pluripotent stem cells is approximately 3×10 4 cells/kg to approximately 3×10 7 cells/kg per individual subject.